Article
Hematology
Cameron Brown, Willem Brandt, Tzu-Fei Wang, Aurelien Delluc, Marc Carrier
Summary: This study assessed the incidence of recurrent venous thromboembolism (VTE) and bleeding complications in patients with cancer and isolated distal deep vein thrombosis (IDDVT). The results showed that these patients are at high risk of developing recurrent VTE and bleeding events, emphasizing the need for further research to determine optimal treatment strategies.
THROMBOSIS RESEARCH
(2023)
Article
Hematology
Hilary Whitworth, Helen Havens Clark, Rebecca A. Hubbard, Char Witmer, Charles E. Leonard, Leslie Raffini
Summary: This study examined the incidence rate of recurrent VTE in pediatric patients with unprovoked VTE, evaluated potential risk factors for recurrence, and described anticoagulation regimens and bleeding in this population. The results showed that age ≥ 12 years and inherited thrombophilia were significantly associated with recurrent VTE. Future research should focus on the efficacy of prolonged anticoagulation for this population.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Hematology
Laura Girardi, Tzu-Fei Wang, Walter Ageno, Marc Carrier
Summary: Patients with cancer have a higher risk of developing venous thromboembolism (VTE) due to specific risk factors and thrombotic and hemostatic pathophysiological pathways. Managing cancer-associated VTE can be challenging due to increased risk of recurrent events and bleeding complications. Direct oral anticoagulants have shown effectiveness, safety, and convenience compared to low-molecular-weight heparin in managing cancer-associated VTE. However, there are still unmet needs and potential solutions, such as factor XI inhibitors, to address bleeding risk, drug interactions, and liver dysfunction.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Article
Medicine, General & Internal
Francois-Xavier Lapebie, Vincent Minville, Agnes Ribes, Bertrand Combis, Arthur Thery, Thomas Geeraerts, Stein Silva, Alessandra Bura-Riviere, Fanny Vardon-Bounes
Summary: This study compared two diagnostic methods for LE-DVT and found that systematic screening did not reduce the diagnosis of VTE or PE in ICU patients with COVID-19.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Chikashi Takeda, Yugo Yamashita, Masato Takeuchi, Hiroshi Yonekura, Li Dong, Miho Hamada, Akiko Hirotsu, Koh Ono, Koji Kawakami, Kazuhiko Fukuda, Takeshi Morimoto, Takeshi Kimura, Toshiyuki Mizota
Summary: This study combines large real-world VTE and anesthesia databases in Japan to evaluate the incidence, clinical characteristics, and prognosis of postoperative symptomatic VTE, providing useful insights for healthcare providers involved in various surgeries.
Article
Oncology
Hirotsugu Kenmotsu, Akifumi Notsu, Keita Mori, Shota Omori, Takahiro Tsushima, Yasuomi Satake, Yoshihiro Miki, Masakazu Abe, Masahito Ogiku, Toshio Nakamura, Masakazu Takagi, Hideto Ochiai, Hirofumi Yasui, Toshiaki Takahashi
Summary: This study revealed a high incidence of VTE in patients with advanced cancer, particularly in those with lung cancer. Although most VTE cases were asymptomatic, intensive screening may be necessary, especially for female patients with elevated D-dimer levels and decreased platelet counts.
Article
Oncology
Derman Basaran, Thomas Boerner, Jessa Suhner, Dib Sassine, Ying Liu, Rachel N. Grisham, William P. Tew, Ginger J. Gardner, Oliver Zivanovic, Yukio Sonoda, Kara Long Roche, Dennis S. Chi, Nadeem R. Abu-Rustum, Gerald A. Soff, Elizabeth L. Jewell
Summary: The study aimed to determine the incidence of VTE in patients receiving neoadjuvant chemotherapy for ovarian cancer, finding that FIGO stage IV disease was the only factor associated with increased risk for new-onset VTE.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Hematology
Anjlee Mahajan, Ann Brunson, Joanna Eldredge, Richard H. White, Theresa H. M. Keegan, Ted Wun
Summary: This study aimed to investigate the epidemiology of isolated distal deep venous thrombosis (iDDVT) among cancer patients, including the incidence of recurrent venous thromboembolism (rVTE) and its effect on mortality by cancer type. The findings showed that iDDVT accounted for 11% of cancer-associated thrombosis (CT), and the risk of rVTE after iDDVT was similar to other CT sites. Furthermore, iDDVT was associated with increased mortality, with similar effects to pulmonary embolism or proximal DVT for most cancer types, except lung, colorectal, bladder, uterine, brain, and myeloma.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
Hanke M. G. Wiegers, Mirte Schaafsma, Noori A. M. Guman, Hein S. Zelisse, Frits I. Mulder, Saskia Middeldorp, Nick van Es, Constantijne H. Mom
Summary: This study aimed to assess the incidence of VTE and bleeding within 30 days following major surgery in patients with ovarian cancer and evaluate the association between VTE and thromboprophylaxis duration. The study found that the cumulative incidence of VTE was considerable in patients with ovarian cancer following major surgery, but extended thromboprophylaxis did not significantly lower the risk of VTE. Overall, the importance of this article is 7 out of 10.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Gary E. Raskob, Aaron M. Wendelboe, Janis Campbell, Lance Ford, Kai Ding, Dale W. Bratzler, Micah McCumber, Alys Adamski, Karon Abe, Michele G. Beckman, Nimia L. Reyes, Lisa C. Richardson
Summary: This study evaluated the incidence and burden of cancer-associated venous thromboembolism (VTE) in Oklahoma County, and found significant differences in incidence rates among different racial and ethnic groups.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
Florian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann, Christoph Hoeller, Felix Tuchmann, Marie-Bernadette Aretin, Thorsten Fuereder, Sabine Zoechbauer-Mueller, Matthias Preusser, Ingrid Pabinger, Cihan Ay
Summary: The study found that cancer patients undergoing therapy with immune checkpoint inhibitors were at a high risk of thromboembolism, particularly venous thromboembolism (VTE). The occurrence of VTE was associated with increased mortality. Patients with a history of VTE were more likely to develop VTE, and distant metastasis may be related to VTE risk.
Article
Hematology
Randa G. Hanna-Sawires, Jesse Groen, Alexander Hamming, Rob A. E. M. Tollenaar, Wilma E. Mesker, Saskia A. C. Luelmo, Alexander L. Vahrmeijer, Bert A. Bonsing, Henri H. Versteeg, F. A. Klok, J. Sven D. Mieog
Summary: VTE in patients with pancreatic cancer is stage-dependent, with most cases occurring in advanced stages of the disease after cessation of active treatment. Stage IV pancreatic cancer is a predictor for VTE, while biliary drainage and tumor resection are protective factors. VTE is not directly associated with worse survival outcomes.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Lara De Lucchi, Chiara Nardin, Alessandra Sponchiado, Davide Raggi, Elisabetta Faggin, Elena Martini, Valeria Pagliara, Elena Callegari, Livio Caberlotto, Mario Plebani, Paolo Pauletto, Francesco Cinetto, Carlo Agostini, Sabina Villalta, Marcello Rattazzi
Summary: Elevated serum uric acid levels are associated with increased risk of future VTE recurrence independently from traditional risk factors. Patients in the lower tertile of SUA distribution had significantly lower risk of future VTE recurrence, while each additional unit of SUA (mg/dL) increased the hazard of VTE recurrence by 30%.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Pharmacology & Pharmacy
Ruihao Li, Manqiu Yuan, Shixiong Yu, Wenlong Fu, Wu Yu, Siying Ling, Jianming Sun, Yikuan Chen
Summary: The use of statins may reduce the risk of disease recurrence and all-cause mortality in patients with VTE. However, further randomized clinical trials are needed to better explore the effect of statins in secondary prevention of VTE.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Clinical Neurology
Liqi Shu, Ekaterina Bakradze, Setareh Salehi Omran, James Giles, Jordan Amar, Nils Henninger, Marwa Elnazeir, Ava Liberman, Khadean Moncrieffe, Jenny Rotblat, Richa Sharma, Yee Cheng, Adeel S. Zubair, Alexis Simpkins, Grace Li, Justin Kung, Dezaray Perez, Mirjam R. Heldner, Adrian Scutelnic, Rascha Von Martial, Bernhard Siepen, Aaron Rothstein, Ossama Khazaal, David Do, Sami Al Kasab, Line Abdul Rahman, Eva A. Mistry, Deborah Kerrigan, Hayden Lafever, Thanh N. Nguyen, Piers Klein, Hugo J. Aparicio, Jennifer A. Frontera, Lindsey Kuohn, Shashank Agarwal, Christoph Stretz, Narendra Kala, Sleiman ElJamal, Allison Chang, Shawna Cutting, Fransisca Indraswari, Adam de Havenon, Varsha Muddasani, Teddy Wu, Duncan Wilson, Amre Nouh, Daniyal Asad, Abid Qureshi, Justin Moore, Pooja Khatri, Yasmin Aziz, Bryce Casteigne, Muhib Khan, Yao Cheng, Brian MacGrory, Martin Weiss, Dylan Ryan, Maria Cristina Vedovati, Maurizio Paciaroni, James Siegler, Scott Kamen, Siyuan Yu, Christopher Leon Guerrero, Eugenie Atallah, Gian Marco De Marchis, Alex Brehm, Tolga Dittrich, Marios Psychogios, Ronald Alvarado-Dyer, Tareq Kass-Hout, Shyam Prabhakaran, Tristan Honda, David Liebeskind, Karen Furie, Shadi Yaghi
Summary: This study aimed to identify predictors of recurrent venous thrombosis in patients with CVT. The study found that Black race, history of VTE, and the presence of one or more positive antiphospholipid antibodies were associated with recurrent venous thrombosis among patients with CVT.